insulin aspart - αποτελεσματα

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

inpremzia

baxter holding b.v. - insulin human (rdna) - diabete mellito - farmaci usati nel diabete - inpremzia is indicated for the treatment of diabetes mellitus.

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

abasaglar cartouche 100 u/ml soluzione iniettabile

eli lilly (suisse) sa - insulinum glarginum - soluzione iniettabile - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., glycerolum, metacresolum, zincum ut zinci oxidum, acidum hydrochloridum dilutum, natrii hydroxidum corresp. natrium 0.04 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

suliqua 100/50 soluzione iniettabile

sanofi-aventis (suisse) sa - insulinum glarginum, lixisenatidum - soluzione iniettabile - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., lixisenatidum 50 µg, zinci chloridum, glycerolum (85 per centum), methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

suliqua 100/33 soluzione iniettabile

sanofi-aventis (suisse) sa - insulinum glarginum, lixisenatidum - soluzione iniettabile - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., lixisenatidum 33 µg, zinci chloridum, glycerolum (85 per centum), methioninum, conserv.: metacresolum 2.7 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

suliqua

sanofi winthrop industrie - l'insulina glargine, lixisenatide - diabete mellito, tipo 2 - farmaci usati nel diabete - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.